Key insights
- Innate Pharma's MATISSE trial (Phase 2) showed promising pathological complete response rates for IPH5201 in lung cancer patients with PD-L1 expression. While positive, the single-arm study and interim nature limit broad market implications. Continued recruitment and further data are needed to assess the true impact on the US equity market.
Innate Pharma SA (Euronext Paris: IPH; NASDAQ: IPHA) announced that interim results from its MATISSE Phase 2 study will be presented at the Clinical Trials Plenary Session during the American Association for Cancer Research Annual Meeting 2026 on April 21 in San Diego.
The MATISSE study evaluates IPH5201, an anti-CD39 monoclonal antibody, combined with durvalumab and platinum-based chemotherapy in patients with resectable non-small cell lung cancer. The single-arm Phase 2 trial examines whether dual inhibition of CD39 and PD-L1 pathways with chemotherapy can enhance anti-tumor immune responses.
An interim analysis of 40 patients showed pathological complete response rates of 35.7% in patients with tumors expressing PD-L1 ≥1% and 50% in those with PD-L1 ≥50% expression. Based on these results, the study continues recruiting patients with PD-L1≥1% tumor expression.
IPH5201 is a monoclonal antibody targeting CD39, an enzyme in the adenosine pathway that contributes to immunosuppression. The drug is being co-developed with AstraZeneca. Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma, stated that disrupting the adenosine pathway through CD39 inhibition could enhance anti-tumor immune responses, particularly in PD-L1 positive tumors.
The MATISSE trial is designed to assess anti-tumor activity and safety to determine whether dual pathway inhibition can improve clinical outcomes in early-stage lung cancer. The company will make the presentation available on its website following the conference.